Literature DB >> 1979924

Pharmacokinetics of pafenolol in the rat: a suitable model for studying absorption mechanisms of a drug exhibiting unusual absorption properties in man.

H Lenneräs1, C G Regårdh.   

Abstract

The pharmacokinetics of pafenolol, a highly selective beta 1-adrenoceptor antagonist, have been studied in starved and unstarved rats. Separate groups received intravenous doses (0.3 and 3.0 mumol kg-1) and oral doses (1 and 25 mumol kg-1). The systemic clearance of pafenolol was constant in the dose range investigated where the absolute oral bioavailability increased from 15 to 27 per cent in the starved and from 9.1 to 21 per cent in the unstarved rats, when the oral dose was raised from 1 to 25 mumol kg-1. The blood concentration profile after an oral solution of pafenolol exhibited two peaks in the majority of the rats. The major part of the absorption was associated with the second peak which appeared about 4 h after dosing in both starved and unstarved rats. Food lowered the degree of bioavailability and shifted the tmax1 to about 1 hour compared to half an hour in starved rats. The low bioavailability was primarily due to incomplete uptake from the gastrointestinal tract. Our study shows that pafenolol is absorbed in a similar way to that in man. The mechanisms behind the dose-dependent bioavailability and the two peaks in the absorption profile after an oral solution will be further explained in the rat.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979924     DOI: 10.1002/bdd.2510110707

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  5 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

3.  Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

4.  Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

5.  Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.

Authors:  E Lipka; I D Lee; P Langguth; H Spahn-Langguth; E Mutschler; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1995-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.